CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COGNITION THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.73−0.00 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $65.92M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.0126 (−58.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $65.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.78M
- EPS, diluted
- -$0.19
- Book value per share
- $0.36
- Diluted shares
- 91M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$36.60M
Net income
-$16.78M
EPS, diluted
-$0.19
Free cash flow
–
Reported periodTrailing twelve months